本文關(guān)鍵詞： 絕經(jīng) 乳腺癌 中藥 內(nèi)分泌 化療耐受性 生命質(zhì)量　出處：《遼寧中醫(yī)雜志》2017年02期 　論文類型：期刊論文

【摘要】：目的:探討術(shù)前中藥聯(lián)合內(nèi)分泌治療對(duì)絕經(jīng)后乳腺癌患者化療耐受性及生命質(zhì)量的影響。方法:隨機(jī)數(shù)字表格法將74例絕經(jīng)后乳腺癌患者分為對(duì)照組與觀察組各37例,術(shù)前均接受新輔助化療治療,此外對(duì)照組加以內(nèi)分泌治療,觀察組在對(duì)照組基礎(chǔ)上聯(lián)合中藥治療,比較兩組近期療效、藥物不良反應(yīng)、治療前后T淋巴細(xì)胞指標(biāo)及生存質(zhì)量改善情況。結(jié)果:觀察組近期有效率59.46%較對(duì)照組的51.35%差異無統(tǒng)計(jì)學(xué)意義(P0.05)。兩組內(nèi)分泌治療不良反應(yīng)無顯著差異(P0.05),觀察組化療惡心嘔吐、骨髓抑制發(fā)生率均明顯低于對(duì)照組(P0.05)。與治療前比較,治療2周期觀察組CD3~+/CD8~+顯著下降,CD4~+/CD8~+明顯上升,差異有統(tǒng)計(jì)學(xué)意義(P0.05),且觀察組治療后CD3~+/CD8~+、CD4~+/CD8~+均明顯優(yōu)于對(duì)照組(P0.05)。觀察組治療后生存質(zhì)量改善有效率89.19%顯著高于對(duì)照組的70.27%(P0.05)。結(jié)論:術(shù)前中藥聯(lián)合內(nèi)分泌治療能明顯減輕化療不良反應(yīng),患者耐受性強(qiáng),且能有效改善患者免疫功能,最終提高患者生存質(zhì)量。
[Abstract]:Objective: to investigate the effect of preoperative Chinese medicine combined with endocrine therapy on chemotherapeutic tolerance and quality of life of postmenopausal breast cancer patients. 74 patients with postmenopausal breast cancer were randomly divided into control group and observation group. All patients received neoadjuvant chemotherapy before operation, in addition, the control group was treated with endocrine therapy, and the observation group was treated with traditional Chinese medicine on the basis of the control group. The short-term efficacy and adverse drug reactions were compared between the two groups. Results: there was no significant difference between the observation group (59.46%) and the control group (51.35%) in the improvement of T lymphocyte index and quality of life (P 0.05). There was no significant difference in adverse reactions of endocrine therapy between the two groups (P0.05). The incidence of nausea and vomiting and bone marrow suppression in the observation group was significantly lower than that in the control group (P 0.05). CD4 / / CD8 ~ increased significantly, the difference was statistically significant (P 0.05), and the observation group after treatment CD3 ~ / CD8 ~. CD _ 4 ~ / CD _ 8 ~ + was significantly better than that of control group (P 0.05). The effective rate of life quality improvement in observation group was significantly higher than that in control group (P 0.05) after treatment, and the improvement rate was significantly higher in observation group than in control group (P 0.05). Conclusion: preoperative Chinese medicine combined with endocrine therapy can significantly reduce the adverse reactions of chemotherapy. Patient tolerance, and can effectively improve the immune function of patients, and ultimately improve the quality of life of patients.
【作者單位】： 濟(jì)南市第三人民醫(yī)院保健科;
【分類號(hào)】：R273
【正文快照】： 乳腺癌在40~60歲女性中比較常見,是導(dǎo)致女性死亡的高危疾病之一。目前臨床治療乳腺癌以化療、內(nèi)分泌干預(yù)等綜合治療為主,其中新輔助化療+手術(shù)應(yīng)用較多,術(shù)前通過新輔助化療能有效減少腫瘤分期,縮小病灶,提高保乳術(shù)幾率[1]。近年來臨床發(fā)現(xiàn)激素依賴型乳腺癌患者越來越多,對(duì)絕經(jīng)

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 張瑾,吳咸中,伍孝先;益氣養(yǎng)血顆粒對(duì)絕經(jīng)后乳腺癌患者內(nèi)分泌功能的調(diào)節(jié)作用[J];中國中西醫(yī)結(jié)合外科雜志;1999年06期

，

本文編號(hào)：1442504